17:46 ETALIT Investors Have Opportunity to Lead Alight, Inc. Securities Fraud Lawsuitprnewswire·Apr 7 at 04:47 PMALIT+2.06%
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)MorningStar·Apr 6 at 06:57 AMATRX0.00%AUPH-1.61%
Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.Unusual Whales·Jan 25 at 06:12 PMSBIO-1.47%PBE+1.87%
19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetesprnewswire·Jan 25 at 06:12 PMIBB+0.95%XLV+2.51%
Genezen and Atsena form strategic manufacturing partnership in Jan 2026. Genezen is a gene therapy CDMO, Atsena is a clinical gene therapy company.Unusual Whales·Jan 20 at 07:05 AMFBT+1.81%PBE+1.87%
